KLRS · Kalaris Therapeutics, Inc.

NasdaqHealthcareBiotechnology

Kalaris Therapeutics Inc Is A Clinical-Stage Biopharmaceutical Company Focused On Developing And Commercializing Therapeutics For Prevalent Retinal Diseases. The Company Is Developing Th103, A Novel, Clinical-Stage Anti-Vascular Endothelial Growth Factor Vegf Drug, Engineered To Potentially Provide Longer-Lasting And Increased Anti-Vegf Activity In Patients With Exudative And Neovascular Retinal Diseases. Th103 Is A Fully Humanized Recombinant Fusion Protein, Functioning As A Decoy Receptor (A Vegf Trap), Leveraging Salient Molecular Properties Of The Human Body'S Native, Highest Affinity Vegf Receptor 1.

HealthcareNasdaqUSLow Float

$6.25

+33.0% latest move

Price & move as of the most recent catalyst (Jul 17) — not a live quote.

FLOAT

5.6M

FREE FLOAT %

24%

SHARES O/S

23.8M

MARKET CAP

$53.8M

EXCHANGE

Nasdaq

COUNTRY

KLRS Catalyst History

Regulatory and ClinicalIND Cleared for StudyJul 17, 2026 · 7:02am ET

KLRSKalaris Therapeutics, Inc.

Be early on the next KLRS spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

KLRS · Kalaris Therapeutics, Inc.

KLRS Catalyst History

Kalaris Therapeutics Announces Additional Phase 1a Data Presentation for TH103

Kalaris Therapeutics Announces Additional Phase 1a Data Presentation for TH103